A Randomized, Multi-Center, Investigator-Masked, Parallel Group, Equivalence Study of Once Daily Brimonidine Tartrate Ophthalmic Suspension Compared With Three Times Daily ALPHAGAN-P® in Subjects With Open Angle Glaucoma, or Ocular Hypertension
Not yet recruiting
Phase of Trial: Phase III
Latest Information Update: 01 Aug 2018
At a glance
- Drugs Brimonidine (Primary) ; Brimonidine (Primary)
- Indications Ocular hypertension; Open-angle glaucoma
- Focus Therapeutic Use
- Sponsors Sun Pharma Advanced Research Company
- 23 Jul 2018 Planned initiation date changed from 1 Jun 2018 to 1 Aug 2018.
- 12 Mar 2018 Planned End Date changed from 1 Jul 2019 to 1 Jun 2019.
- 12 Mar 2018 Planned primary completion date changed from 1 May 2019 to 1 Mar 2019.